Developer docs
API playgroundTry for free, no card

Search company profiles

Lyrus

Full company profile

uuid0025lh7

Namestring
Lyrus
Legal namestring
Lyrus Life Science Pvt. Ltd.
Websiteurl
lyruslife.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Lyrus Life Science Pvt. Ltd., headquartered in Bangalore, India and founded in 2015, operates as a contract development and manufacturing organisation (CDMO) serving global pharmaceutical companies across regulated and emerging markets. The company offers end-to-end formulation development services spanning pre-formulation, analytical development, pilot and exhibit manufacturing, regulatory dossier preparation (eCTD, ACTD, ANDA) and commercial-scale manufacturing in cGMP-compliant facilities approved by MHRA, EU GMP, FDA, PICs and TGA. Its proprietary technology platforms centre on Novel Drug Delivery Systems (NDDS), nano-technology for bioavailability enhancement of poorly soluble compounds, controlled-release platforms, and innovative primary packaging such as Air-dose packs and Bag on Valve aerosol sprays.

The company's product portfolio comprises 60+ generic and specialty formulations and 150+ registered SKUs across nine therapeutic segments (Neuropsychiatry, Cardiovascular, Diabetes & Endocrinology, Urology, Gastroenterology, Topicals, Pain Management, Anti-Infectives, OTC & Nutraceuticals) in multiple dosage forms including oral solids, oral liquids, topicals and parenterals. Lyrus monetises through multiple revenue streams: contract development and manufacturing fees, out-licensing of dossiers, technology transfer of in-house developed products to local manufacturers in partner markets, sale of its own generic and specialty formulations through distribution arrangements, and dedicated R&D services including stability studies.

Lyrus maintains a commercial presence across Europe, Africa, Australia, MENA, Asia, the USA and Canada, supported by sales/marketing offices in Uxbridge (UK) and Wilmington (USA). The leadership team brings 300+ years of combined pharmaceutical formulation, manufacturing and global marketing experience, with Rajesh Goel serving as Chief Executive Officer. The company is privately held and appears to be founder/management owned, with no disclosed institutional investors or parent company.

Short descriptiontext

Lyrus Life Science is a Bangalore-based pharmaceutical CDMO offering end-to-end formulation development, regulatory services and cGMP manufacturing to global pharma clients across nine therapeutic segments and multiple dosage forms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBangalore, India
HQ citystring
Bangalore
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulation development, contract development manufacturing, novel drug delivery systems, generic pharmaceutical formulations, regulatory affairs services
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Development and Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Contract Development and Manufacturing (CDMO)
TypeProfessional Services
Description

Contract development and manufacturing of finished formulations for pharmaceutical companies

lyruslife.com
2Dossier Licensing
TypeLicensing Royalties
Description

Out-licensing of developed dossiers with manufacturing in GMP environment

lyruslife.com
3Technology Transfer
TypeLicensing Royalties
Description

Technology transfer of products for local manufacturing in partner markets

lyruslife.com
4R&D Services
TypeProfessional Services
Description

Galenical and analytical development, scale-up, pilot batch manufacturing, and stability studies

lyruslife.com
5Product Sales
TypeOne Time License
Description

Sale of generic and specialty formulations across regulated and emerging markets

lyruslife.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Lyrus is a B2B contract research, development, and manufacturing organization (CDMO) for the pharmaceutical industry. It provides end-to-end formulation development services covering pre-formulation, analytical development, pilot/exhibit manufacturing, regulatory affairs, and commercial manufacturing. The company also develops and out-licenses its own portfolio of generic and specialty formulations across multiple dosage forms (oral solids, liquids, topicals, parenterals) using proprietary platform technologies including NDDS, nano technology, and bioavailability enhancement.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lyrus is a research and technology-driven global specialty pharmaceutical company offering integrated formulation development and manufacturing services. The core offerings consist of Formulation Development, Pre Formulation, Analytical Development, Pilot and Exhibit Manufacturing, Regulatory Services, and Commercial Manufacturing partnerships. The company maintains a portfolio of 60+ generic and specialty formulations across therapeutic segments including Neuropsychiatry, Cardiovascular, Diabetes & Endocrinology, Urology, Gastroenterology, Topicals, Pain Management, Anti-Infectives, and OTC/Nutraceuticals. Products span multiple dosage forms including oral solids, oral liquids, topicals, and parenterals, developed using advanced platform technologies such as Nano Technology, NDDS, Novel Platform Technologies, and Bioavailability enhancement solutions. Services are offered through contract development, out-licensing of dossiers, and technology transfer arrangements across regulated markets including Europe, Australia, Canada, US, and South Africa.

Product and service8 records
1Formulation Development
CategoryPharmaceutical R&D Services
Description

End-to-end formulation development services covering NDDS, Novel Platform Technologies, Nano Technology/Bioavailability enhancement, and Nutraceuticals for oral solids, oral liquids, topicals, and parenterals, offered to pharmaceutical companies globally.

2Pre Formulation
CategoryPharmaceutical R&D Services
Description

Comprehensive pre-formulation studies designed to ensure robust dosage forms that can sustain processing and shelf life rigors, minimizing failure rates and development costs for pharmaceutical clients.

3Analytical Development
CategoryPharmaceutical R&D Services
Description

Dedicated analytical services including API characterization, method development, validation, stability testing, release testing, and reference material qualification under cGMP and ICH guidelines, offered to pharmaceutical customers.

4Pilot and Exhibit Manufacturing
CategoryPharmaceutical Manufacturing Services
Description

Integration of development laboratories with industrial manufacturing facilities for pilot batch production, scale-up studies, and validation of manufacturing processes, offered to pharmaceutical clients.

5Regulatory Services
CategoryPharmaceutical Regulatory Services
Description

Regulatory affairs support including dossier preparation in eCTD, ACTD, ANDA formats, submission procedures (DCP, MRP, National), and regulatory compliance for EMA and FDA markets, offered to pharmaceutical companies.

6Commercial Manufacturing
CategoryPharmaceutical Manufacturing Services
Description

Contract manufacturing partnerships for exhibit and commercial-scale production with facilities approved by MHRA/EU GMP/FDA/PICs/TGA and country-specific authorities, serving pharmaceutical clients globally.

7Generic and Specialty Formulations
CategoryPharmaceutical Products
Description

Portfolio of 60+ products and 150+ SKUs spanning ethical (branded generics), OTC, and nutraceuticals in conventional and novel dosage forms, registered primarily in Africa with expansion into European, Australian, Canadian, US, and South African markets; sold via distribution and licensing partners.

8Contract Research & Development Services
CategoryPharmaceutical R&D Services
Description

Full spectrum CRO services including galenical and analytical development, scale-up, pilot batch manufacturing, stability studies, and technology transfer, offered to pharmaceutical clients along with dossier out-licensing and technology transfer arrangements.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-based specialty generics developer with strong presence in emerging markets and a portfolio of differentiated formulations; comparable to Lyrus on niche generic dossier development and African/regulated market supply.

TypeDirect peer
Description

Global CDMO offering formulation development, API and drug product manufacturing across multiple dosage forms with strong regulatory compliance; competes with Lyrus for contract development and dossier licensing work from innovator and generic companies.

3Syngene International
TypeDirect peer
Description

India-headquartered CRO/CDMO providing formulation development, analytical services and contract manufacturing for global pharma, directly comparable to Lyrus on the formulation development and contract manufacturing axis.

TypeBroad incumbent
Description

Major Indian generic and API manufacturer with extensive formulation development, dossier and contract manufacturing capabilities; competes with Lyrus on generic formulation licensing and supply into Africa and other emerging markets.

5Recipharm
TypeBroad incumbent
Description

European-headquartered CDMO offering formulation development, manufacturing and technology transfer across multiple dosage forms; comparable to Lyrus for European and emerging-market contract engagements.

TypeBroad incumbent
Description

Global CDMO leader with broad formulation, softgel, biologics and oral drug product capabilities; represents the large incumbent Lyrus competes against for complex formulation and bioavailability-enhancement deals.

TypeDirect peer
Description

India-based integrated CDMO offering solid dosage formulations, parenterals and contract research services to global pharma; overlaps Lyrus on dossier development, scale-up and commercial supply for regulated markets.

TypeBroad incumbent
Description

Global CDMO offering drug product and API services including small molecule oral solid dosage forms; competes at the high end of the CDMO market and establishes the scale benchmark Lyrus's customers compare against.

TypeBroad incumbent
Description

Large India-headquartered generics and API player with a substantial contract development services arm covering formulation development and manufacturing across multiple dosage forms; broader portfolio but directly competing for the same CDMO engagements.

TypeRegional player
Description

India-headquartered API and formulation manufacturer with custom synthesis and CDMO services; adjacent peer focused more on APIs but overlaps Lyrus on contract development and emerging-market generic supply.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyrus

Pharmaceutical Contract Development and Manufacturinglyruslife.com

Lyrus Life Science is a Bangalore-based pharmaceutical CDMO offering end-to-end formulation development, regulatory services and cGMP manufacturing to global pharma clients across nine therapeutic segments and multiple dosage forms.

What Lyrus does

Lyrus Life Science Pvt. Ltd., headquartered in Bangalore, India and founded in 2015, operates as a contract development and manufacturing organisation (CDMO) serving global pharmaceutical companies across regulated and emerging markets. The company offers end-to-end formulation development services spanning pre-formulation, analytical development, pilot and exhibit manufacturing, regulatory dossier preparation (eCTD, ACTD, ANDA) and commercial-scale manufacturing in cGMP-compliant facilities approved by MHRA, EU GMP, FDA, PICs and TGA. Its proprietary technology platforms centre on Novel Drug Delivery Systems (NDDS), nano-technology for bioavailability enhancement of poorly soluble compounds, controlled-release platforms, and innovative primary packaging such as Air-dose packs and Bag on Valve aerosol sprays.

The company's product portfolio comprises 60+ generic and specialty formulations and 150+ registered SKUs across nine therapeutic segments (Neuropsychiatry, Cardiovascular, Diabetes & Endocrinology, Urology, Gastroenterology, Topicals, Pain Management, Anti-Infectives, OTC & Nutraceuticals) in multiple dosage forms including oral solids, oral liquids, topicals and parenterals. Lyrus monetises through multiple revenue streams: contract development and manufacturing fees, out-licensing of dossiers, technology transfer of in-house developed products to local manufacturers in partner markets, sale of its own generic and specialty formulations through distribution arrangements, and dedicated R&D services including stability studies.

Lyrus maintains a commercial presence across Europe, Africa, Australia, MENA, Asia, the USA and Canada, supported by sales/marketing offices in Uxbridge (UK) and Wilmington (USA). The leadership team brings 300+ years of combined pharmaceutical formulation, manufacturing and global marketing experience, with Rajesh Goel serving as Chief Executive Officer. The company is privately held and appears to be founder/management owned, with no disclosed institutional investors or parent company.

Lyrus firmographics

Firmographics
Name
Lyrus
Legal name
Lyrus Life Science Pvt. Ltd.
Website
https://lyruslife.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Lyrus Life Science is a Bangalore-based pharmaceutical CDMO offering end-to-end formulation development, regulatory services and cGMP manufacturing to global pharma clients across nine therapeutic segments and multiple dosage forms.
Ownership category
akta.pro rank

Lyrus industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical formulation development
  • Contract development manufacturing
  • Novel drug delivery systems
  • Generic pharmaceutical formulations
  • Regulatory affairs services

Where Lyrus is headquartered

Location

Headquarters

HQ city
Bangalore
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Lyrus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing (CDMO): Contract development and manufacturing of finished formulations for pharmaceutical companies
  2. Dossier Licensing: Out-licensing of developed dossiers with manufacturing in GMP environment
  3. Technology Transfer: Technology transfer of products for local manufacturing in partner markets
  4. R&D Services: Galenical and analytical development, scale-up, pilot batch manufacturing, and stability studies
  5. Product Sales: Sale of generic and specialty formulations across regulated and emerging markets

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Lyrus product offering

Product offering

Core offering

Lyrus is a B2B contract research, development, and manufacturing organization (CDMO) for the pharmaceutical industry. It provides end-to-end formulation development services covering pre-formulation, analytical development, pilot/exhibit manufacturing, regulatory affairs, and commercial manufacturing. The company also develops and out-licenses its own portfolio of generic and specialty formulations across multiple dosage forms (oral solids, liquids, topicals, parenterals) using proprietary platform technologies including NDDS, nano technology, and bioavailability enhancement.

Product overview

Lyrus is a research and technology-driven global specialty pharmaceutical company offering integrated formulation development and manufacturing services. The core offerings consist of Formulation Development, Pre Formulation, Analytical Development, Pilot and Exhibit Manufacturing, Regulatory Services, and Commercial Manufacturing partnerships. The company maintains a portfolio of 60+ generic and specialty formulations across therapeutic segments including Neuropsychiatry, Cardiovascular, Diabetes & Endocrinology, Urology, Gastroenterology, Topicals, Pain Management, Anti-Infectives, and OTC/Nutraceuticals. Products span multiple dosage forms including oral solids, oral liquids, topicals, and parenterals, developed using advanced platform technologies such as Nano Technology, NDDS, Novel Platform Technologies, and Bioavailability enhancement solutions. Services are offered through contract development, out-licensing of dossiers, and technology transfer arrangements across regulated markets including Europe, Australia, Canada, US, and South Africa.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation Development End-to-end formulation development services covering NDDS, Novel Platform Technologies, Nano Technology/Bioavailability enhancement, and Nutraceuticals for oral solids, oral liquids, topicals, and parenterals, offered to pharmaceutical companies globally.
  • Pre Formulation Comprehensive pre-formulation studies designed to ensure robust dosage forms that can sustain processing and shelf life rigors, minimizing failure rates and development costs for pharmaceutical clients.
  • Analytical Development Dedicated analytical services including API characterization, method development, validation, stability testing, release testing, and reference material qualification under cGMP and ICH guidelines, offered to pharmaceutical customers.
  • Pilot and Exhibit Manufacturing Integration of development laboratories with industrial manufacturing facilities for pilot batch production, scale-up studies, and validation of manufacturing processes, offered to pharmaceutical clients.
  • Regulatory Services Regulatory affairs support including dossier preparation in eCTD, ACTD, ANDA formats, submission procedures (DCP, MRP, National), and regulatory compliance for EMA and FDA markets, offered to pharmaceutical companies.
  • Commercial Manufacturing Contract manufacturing partnerships for exhibit and commercial-scale production with facilities approved by MHRA/EU GMP/FDA/PICs/TGA and country-specific authorities, serving pharmaceutical clients globally.
  • Generic and Specialty Formulations Portfolio of 60+ products and 150+ SKUs spanning ethical (branded generics), OTC, and nutraceuticals in conventional and novel dosage forms, registered primarily in Africa with expansion into European, Australian, Canadian, US, and South African markets; sold via distribution and licensing partners.
  • Contract Research & Development Services Full spectrum CRO services including galenical and analytical development, scale-up, pilot batch manufacturing, stability studies, and technology transfer, offered to pharmaceutical clients along with dossier out-licensing and technology transfer arrangements.

Companies that use Lyrus

Customer profile

Segments3 records

Ideal customer profiles2 records

Lyrus technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Lyrus partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Lyrus competitors and assessment

Company assessment

Direct peers

  • Strides Pharma: India-based specialty generics developer with strong presence in emerging markets and a portfolio of differentiated formulations; comparable to Lyrus on niche generic dossier development and African/regulated market supply.
  • Piramal Pharma Solutions: Global CDMO offering formulation development, API and drug product manufacturing across multiple dosage forms with strong regulatory compliance; competes with Lyrus for contract development and dossier licensing work from innovator and generic companies.
  • Syngene International: India-headquartered CRO/CDMO providing formulation development, analytical services and contract manufacturing for global pharma, directly comparable to Lyrus on the formulation development and contract manufacturing axis.
  • Jubilant Pharmova: India-based integrated CDMO offering solid dosage formulations, parenterals and contract research services to global pharma; overlaps Lyrus on dossier development, scale-up and commercial supply for regulated markets.

Broad incumbents

  • Aurobindo Pharma: Major Indian generic and API manufacturer with extensive formulation development, dossier and contract manufacturing capabilities; competes with Lyrus on generic formulation licensing and supply into Africa and other emerging markets.
  • Recipharm: European-headquartered CDMO offering formulation development, manufacturing and technology transfer across multiple dosage forms; comparable to Lyrus for European and emerging-market contract engagements.
  • Catalent: Global CDMO leader with broad formulation, softgel, biologics and oral drug product capabilities; represents the large incumbent Lyrus competes against for complex formulation and bioavailability-enhancement deals.
  • Lonza (Pharma & Biotech): Global CDMO offering drug product and API services including small molecule oral solid dosage forms; competes at the high end of the CDMO market and establishes the scale benchmark Lyrus's customers compare against.
  • Dr. Reddy's Laboratories (Custom Pharma Services): Large India-headquartered generics and API player with a substantial contract development services arm covering formulation development and manufacturing across multiple dosage forms; broader portfolio but directly competing for the same CDMO engagements.

Regional players

  • Laurus Labs: India-headquartered API and formulation manufacturer with custom synthesis and CDMO services; adjacent peer focused more on APIs but overlaps Lyrus on contract development and emerging-market generic supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lyrus social profiles

Digital presence

Lyrus compliance and trust

Trust signal

Compliance2 records

Lyrus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyrus leadership team

Management profile

Number of profiles

Profiles1 record

Lyrus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyrus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyrus

What does Lyrus do?

Lyrus is a B2B contract research, development, and manufacturing organization (CDMO) for the pharmaceutical industry. It provides end-to-end formulation development services covering pre-formulation, analytical development, pilot/exhibit manufacturing, regulatory affairs, and commercial manufacturing. The company also develops and out-licenses its own portfolio of generic and specialty formulations across multiple dosage forms (oral solids, liquids, topicals, parenterals) using proprietary platform technologies including NDDS, nano technology, and bioavailability enhancement.

Is Lyrus a public or private company?

Lyrus is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lyrus founded?

Lyrus was founded in 2015. It employs 101 to 250 people.

Where is Lyrus based?

Lyrus is headquartered in Bangalore, India, in the Asia region.

How does Lyrus make money?

Five revenue lines are on record. Contract Development and Manufacturing (CDMO) is the primary driver. The others are dossier Licensing, technology Transfer, R&D Services and product Sales.

Who are Lyrus's main competitors?

Direct peers on record are Strides Pharma, Piramal Pharma Solutions, Syngene International and Jubilant Pharmova. Broad incumbents are Aurobindo Pharma, Recipharm, Catalent, Lonza (Pharma & Biotech) and Dr. Reddy's Laboratories (Custom Pharma Services). Laurus Labs is listed as a regional player.

Does Lyrus have an API?

No public API is recorded for Lyrus.

What industry is Lyrus in?

Lyrus's product category is Pharmaceutical Contract Development and Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales